Comparison of the Efficacy of Levothyroxine Suppression Dose Computed Based on Actual Body Weight vs. Lean Body Mass among Differentiated Thyroid Cancer Patients: A Randomized Controlled Trial
Objective. Comparison of the efficacy of two methods of computation for the initial levothyroxine dose in patients with differentiated thyroid cancer based on actual body weight vs. lean body mass in achieving thyroid-stimulating hormone (TSH) goals.
Methodology. Randomized, single-center, 12-week open label controlled trial among adult patients with differentiated thyroid cancer post total thyroidectomy who underwent radioactive therapy at St. Luke’s Medical Center Quezon City from July-December 2018. Participants were divided into 2 groups - Actual Body Weight (ABW) and Lean Body Mass (LBM). Levothyroxine dose was computed based on ABW vs. LBM and TSH determined at 6th and 12th weeks after.
Results. Fifty-two participants (ABW n=26; LBM n=26) were included. ABW group had significantly higher mean LT4 dosage (2.2 mcg/kg) compared to the LBM group (1.4 mcg/kg) (p-valuep-value=0.064). A significantly lower TSH level was observed at week 12 in the ABW group (1.6 uIU/mL) compared to the LBM group (3.8 uIU/mL) (p-value=0.010). However, both methods were not associated with achievement of TSH goal at 6th and 12th week (p-value=0.512 and 0.780, respectively).
Conclusion. Among patients with differentiated thyroid cancer who underwent 1st time RAI therapy, ABW method of computation for LT4 dosage is better compared to the LBM method due to the lower TSH trend seen at 6th week and statistically significantly lower mean TSH at week 12, although, both method of computations did not achieve target TSH levels at the 6th nor 12th week.
Baehr KM, Lyden E, Treude K, Erickson J, Goldner W Levothyroxine dose following thyroidectomy is affected by more than just body weight. Laryngoscope. 2012;122(4):834-8. PMID: 22374624. https://doi.org/10.1002/lary.23186.
Burmeister LA, Goumaz MO, Mariash CN, Oppenheimer JH.
Levothyroxine dose requirements for thyrotropin suppression in
the treatment of differentiated thyroid cancer. J Clin Endocrinol
Metabol. 1992;75(2):344-50. PMID: 1639933. https://doi.org/10.1210/jcem.75.2.1639933.
Jin J, Allemang MT, McHenry CR. Levothyroxine replacement dosage determination after thyroidectomy. Am J Surg. 2013;205(3):360-3; discussion 363-4. PMID: 23369308. https://doi.org/10.1016/j.amjsurg.2012.10.015.
Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: Prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670-751. PMID: 25266247. PMCID: PMC4267409. https://doi.org/10.1089/thy.2014.0028.
Cunningham JJ, Barzel US. Lean body mass is a predictor of the daily requirement for thyroid hormone in older men and women. J Am Geriatr Soc. 1984;32(3):204-7. PMID: 6699335. https://doi.org/10.1111/j.1532-5415.1984.tb02003.x.
Kulkarni B, Kuper H, Taylor A, et al. Development and validation of anthropometric prediction equations for estimation of lean body mass and appendicular lean soft tissue in Indian men and women. J Appl Physiol (1985). 2013;115(8):1156-62. PMID: 23950165. PMCID: PMC3798815. https://doi.org/10.1152/japplphysiol.00777.2013.
Sukumar R, Agarwal A, Gupta S, et al. Prediction of LT4
replacement dose to achieve euthyroidism in subjects undergoing total thyroidectomy for benign thyroid disorders. World J Surg. 2010;34(3):527-31. PMID: 20044749. https://doi.org/10.1007/s00268-009-0345-3.
Santini F, Pinchera A, Marsili A, et al. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J Clin Endocrinol Metab. 2005;90(1)124-7. PMID: 15483074. https://doi.org/10.1210/jc.2004-1306.
Begum F, Ahmed CM, Afroz S, et al. Lean body mass-based
levothyroxine replacement in young athyrotic patients with
differentiated carcinoma of thyroid. Indian J Endocrinol
Metab. 2013;17(2):254-9. PMID: 23776898. PMCID: PMC3683200.https://doi.org/10.4103/2230-8210.109697.
Roubenoff R, Kehayias JJ. The meaning and measurement of lean body mass. Nutr Rev. 1991;49(6):163-75. PMID: 2046978. https://doi.org/10.1111/j.1753-4887.1991.tb03013.x.
Olubowale O, Chadwick DR. Optimization of thyroxine replacement
therapy after total or near-total thyroidectomy for benign thyroid
disease. Br J Surg. 2006;93(1):57-60. PMID: 16323163. https://doi.org/10.1002/bjs.5157.
Copyright (c) 2019 Journal of the ASEAN Federation of Endocrine Societies
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of the ASEAN Federation of Endocrine Societies is licensed under a Creative Commons Attribution-NonCommercial 4.0 International. (full license at this link: http://creativecommons.org/licenses/by-nc/3.0/legalcode).
To obtain permission to translate/reproduce or download articles or use images FOR COMMERCIAL REUSE/BUSINESS PURPOSES from the Journal of the ASEAN Federation of Endocrine Societies, kindly fill in the Permission Request for Use of Copyrighted Material and return as PDF file to firstname.lastname@example.org or email@example.com.
A written agreement shall be emailed to the requester should permission be granted.